http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3735991-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2019-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5808f55cee277858c703f2eaa25440e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566a9a1843400f0dbd79dbe09067b616
publicationDate 2020-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3735991-A1
titleOfInvention Adc for a concomitant or subsequent treatment with docetaxel
abstract The present invention relates to an ADC of the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises CDRs of the light chain of sequences SEQ ID Nos. 9, 5 and 11 respectively and heavy chain CDRs of sequence SEQ ID Nos 7, 2 and 3 respectively, and n is between 1 and 12, for its use in the treatment of proliferative diseases, such as cancer, characterized in that ADC is administered concomitantly or subsequently to docetaxel.
priorityDate 2019-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015162291-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395888
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396057
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6711468
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395512
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8567
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311497
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7618
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID439331987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396694
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399412
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119411
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394721
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID155275001
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64780
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5757
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399366
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208908
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396417
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396418

Total number of triples: 66.